The transglutaminase 2 gene is aberrantly hypermethylated in glioma

Journal of Neuro-Oncology

Volumn 101, Issue 3, 2011, Pages 429-440

  Dyer, Lisa M ^a,b   Schooler, Kevin P ^a   Ai, Lingbao ^a,b   Klop, Corinne ^b   Qiu, Jingxin ^a,b   Robertson, Keith D ^a,b,c   Brown, Kevin D ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Drug resistance; Epigenetic silencing; Extra cellular matrix; Glioma; Tumor invasiveness

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DOXORUBICIN; GENOMIC DNA; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOMUSTINE; MUTANT PROTEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; RECOMBINANT PROTEIN; TRICHOSTATIN A;

ARTICLE; BRAIN TUMOR; CANCER CELL CULTURE; CANCER INVASION; CATALYSIS; CELL INVASION; CONTROLLED STUDY; DATA BASE; DNA FLANKING REGION; DNA METHYLATION; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME ACTIVITY; EPIGENETICS; EXTRACELLULAR MATRIX; GENE; GENE OVEREXPRESSION; GENE SILENCING; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PHENOTYPE; PRIMARY TUMOR; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; TRANSGLUTAMINASE 2 GENE;

ANTIBIOTICS, ANTINEOPLASTIC; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL PROLIFERATION; DNA METHYLATION; DNA, NEOPLASM; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; GTP-BINDING PROTEINS; HUMANS; MUTAGENESIS, SITE-DIRECTED; MUTATION; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; TRANSGLUTAMINASES; TUMOR CELLS, CULTURED;

EID: 79952196448     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0277-7     Document Type: Article

References (58)

1. Weinberg RA (1996) How cancer arises. Sci Am 275:62-70
2. Bird A (1992) The essentials of DNA methylation. Cell 70:5-8
3. Wolffe AP (2001) Chromatin remodeling: why it is important in cancer. Oncogene 20:2988-2990
4. Lorand L, Conrad SM (1984) Transglutaminases. Mol Cell Biochem 58:9-35
5. Aeschlimann D, Thomazy V (2000) Protein crosslinking in assembly and remodelling of extracellular matrices: the role of transglutaminases. Connect Tissue Res 41:1-27 (Pubitemid 30246155)
6. Zemskov EA, Janiak A, Hang J, Waghray A, Belkin AM (2006) The role of tissue transglutaminase in cell-matrix interactions. Front Biosci 11:1057-1076 (Pubitemid 43253460)
7. Telci D, Griffin M (2006) Tissue transglutaminase (TG2) - a wound response enzyme. Front Biosci 11:867-882 (Pubitemid 43258187)
8. Haroon ZA, Lai TS, Hettasch JM, Lindberg RA, Dewhirst MW, Greenberg CS (1999) Tissue transglutaminase is expressed as a host response to tumor invasion and inhibits tumor growth. Lab Invest 79:1679-1686 (Pubitemid 30013931)
9. Jones RA, Kotsakis P, Johnson TS et al (2006) Matrix changes induced by transglutaminase 2 lead to inhibition of angiogenesis and tumor growth. Cell Death Differ 13:1442-1453 (Pubitemid 44210348)
10. Mehta K (1994) High levels of transglutaminase expression in doxorubicin-resistant human breast carcinoma cells. Int J Cancer 58:400-406
11. Yuan L, Choi K, Khosla C et al (2005) Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas. Mol Cancer Ther 4:1293-1302
12. Chen JS, Agarwal N, Mehta K (2002) Multidrug-resistant MCF-7 breast cancer cells contain deficient intracellular calcium pools. Breast Cancer Res Treat 71:237-247 (Pubitemid 34263987)
13. Han JA, Park SC (1999) Reduction of transglutaminase 2 expression is associated with an induction of drug sensitivity in the PC-14 human lung cancer cell line. J Cancer Res Clin Oncol 125:89-95 (Pubitemid 29161460)
14. Herman JF, Mangala LS, Mehta K (2006) Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells. Oncogene 25:3049-3058 (Pubitemid 43780469)
15. Kim DS, Park SS, Nam BH, Kim IH, Kim SY (2006) Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation. Cancer Res 66:10936-10943
16. Mann AP, Verma A, Sethi G et al (2006) Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-{kappa}B in cancer cells: delineation of a novel pathway. Cancer Res 66:8788-8795 (Pubitemid 44449196)
17. Kotsakis P, Griffin M (2007) Tissue transglutaminase in tumour progression: friend or foe? Amino Acids 33:373-384
18. Chhabra A, Verma A, Mehta K (2009) Tissue transglutaminase promotes or suppresses tumors depending on cell context. Anticancer Res 29:1909-1919
19. Partap S, Fisher PG (2007) Update on new treatments and developments in childhood brain tumors. Curr Opin Pediatr 19:670-674 (Pubitemid 350145235)
20. Nieder C, Mehta MP, Jalali R (2009) Combined radio- and chemotherapy of brain tumours in adult patients. Clin Oncol (R Coll Radiol) 21:515-524
21. Bellail AC, Hunter SB, Brat DJ, Tan C, Van Meir EG (2004) Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell Biol 36: 1046-1069
22. Nieder C, Adam M, Molls M, Grosu AL (2006) Therapeutic options for recurrent high-grade glioma in adult patients: recent advances. Crit Rev Oncol Hematol 60:181-193
23. Hunter SB, Brat DJ, Olson JJ, Von Deimling A, Zhou W, Van Meir EG (2003) Alterations in molecular pathways of diffusely infiltrating glial neoplasms: application to tumor classification and anti-tumor therapy (Review). Int J Oncol 23:857-869
24. Liotta LA, Steeg PS, Stetler-Stevenson WG (1991) Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64:327-336
25. Vu TH, Werb Z (2000) Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 14:2123-2133
26. Jaworski DM, Kelly GM, Piepmeier JM, Hockfield S (1996) BEHAB (brain enriched hyaluronan binding) is expressed in surgical samples of glioma and in intracranial grafts of invasive glioma cell lines. Cancer Res 56:2293-2298
27. Koochekpour S, Pilkington GJ, Merzak A (1995) Hyaluronic acid/CD44H interaction induces cell detachment and stimulates migration and invasion of human glioma cells in vitro. Int J Cancer 63:450-454
28. Koochekpour S, Merzak A, Pilkington GJ (1995) Extracellular matrix proteins inhibit proliferation, upregulate migration and induce morphological changes in human glioma cell lines. Eur J Cancer 31A:375-380
29. Paulus W, Baur I, Dours-Zimmermann MT, Zimmermann DR (1996) Differential expression of versican isoforms in brain tumors. J Neuropathol Exp Neurol 55:528-533
30. Nakada M, Nakada S, Demuth T, Tran NL, Hoelzinger DB, Berens ME (2007) Molecular targets of glioma invasion. Cell Mol Life Sci 64:458-478
31. Paulus W, Tonn JC (1995) Interactions of glioma cells and extracellular matrix. J Neurooncol 24:87-91
32. Ai L, Kim WJ, Demircan B et al (2008) The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer. Carcinogenesis 29:510-518
33. Qiu J, Ai L, Ramachandran C et al (2008) Invasion suppressor cystatin E/M (CST6): high-level cell type-specific expression in normal brain and epigenetic silencing in gliomas. Lab Invest 88:910-925
34. Demircan B, Dyer LM, Gerace M, Lobenhofer EK, Robertson KD, Brown KD (2009) Comparative epigenomics of human and mouse mammary tumors. Genes Chromosomes Cancer 48:83-97
35. Chalmers-Redman RM, Priestley T, Kemp JA, Fine A (1997) In vitro propagation and inducible differentiation of multipotential progenitor cells from human fetal brain. Neuroscience 76:1121-1128
36. Yuan L, Siegel M, Choi K et al (2006) Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene 26:2563-2573
37. Verma A, Mehta K (2007) Tissue transglutaminase-mediated chemoresistance in cancer cells. Drug Resist Updat 10:144-151
38. Murthy SN, Iismaa S, Begg G, Freymann DM, Graham RM, Lorand L (2002) Conserved tryptophan in the core domain of transglutaminase is essential for catalytic activity. Proc Natl Acad Sci USA 99:2738-2742
39. Levicar N, Strojnik T, Kos J, Dewey RA, Pilkington GJ, Lah TT (2002) Lysosomal enzymes, cathepsins in brain tumour invasion. J Neurooncol 58:21-32
40. Johnson TS, Knight CR, el-Alaoui S et al (1994) Transfection of tissue transglutaminase into a highly malignant hamster fibrosarcoma leads to a reduced incidence of primary tumour growth. Oncogene 9:2935-2942
41. Jones RA, Nicholas B, Mian S, Davies PJ, Griffin M (1997) Reduced expression of tissue transglutaminase in a human endothelial cell line leads to changes in cell spreading, cell adhesion and reduced polymerisation of fibronectin. J Cell Sci 110(Pt 19):2461-2472
42. Verderio E, Nicholas B, Gross S, Griffin M (1998) Regulated expression of tissue transglutaminase in Swiss 3T3 fibroblasts: effects on the processing of fibronectin, cell attachment, and cell death. Exp Cell Res 239:119-138
43. Balklava Z, Verderio E, Collighan R, Gross S, Adams J, Griffin M (2002) Analysis of tissue transglutaminase function in the migration of Swiss 3T3 fibroblasts: the active-state conformation of the enzyme does not affect cell motility but is important for its secretion. J Biol Chem 277:16567-16575
44. Mangala LS, Arun B, Sahin AA, Mehta K (2005) Tissue transglutaminase- induced alterations in extracellular matrix inhibit tumor invasion. Mol Cancer 4:33
45. Mangala LS, Fok JY, Zorrilla-Calancha IR, Verma A, Mehta K (2007) Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells. Oncogene 26:2459-2470
46. Satpathy M, Cao L, Pincheira R et al (2007) Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase. Cancer Res 67:7194-7202
47. Verma A, Guha S, Diagaradjane P et al (2008) Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res 14:2476-2483
48. Antonyak MA, Li B, Regan AD, Feng Q, Dusaban SS, Cerione RA (2009) Tissue transglutaminase is an essential participant in the epidermal growth factor-stimulated signaling pathway leading to cancer cell migration and invasion. J Biol Chem 284:17914-17925
49. Lee J, Kim YS, Choi DH et al (2004) Transglutaminase 2 induces nuclear factor-kappaB activation via a novel pathway in BV-2 microglia. J Biol Chem 279:53725-53735
50. Nabel G, Baltimore D (1987) An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 326:711-713
51. Ghosh S, May MJ, Kopp EB (1998) NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16:225-260
52. Karin M, Cao Y, Greten FR, Li ZW (2002) NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2:301-310
53. Nagai S, Washiyama K, Kurimoto M, Takaku A, Endo S, Kumanishi T (2002) Aberrant nuclear factor-kappaB activity and its participation in the growth of human malignant astrocytoma. J Neurosurg 96:909-917
54. Wang H, Zhang W, Huang HJ, Liao WS, Fuller GN (2004) Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas. Lab Invest 84:941-951
55. Cao L, Petrusca DN, Satpathy M, Nakshatri H, Petrache I, Matei D (2008) Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. Carcinogenesis 29:1893-1900
56. Park KS, Kim HK, Lee JH et al (2010) Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer. J Cancer Res Clin Oncol 136:493-502
57. Antonyak MA, Singh US, Lee DA et al (2001) Effects of tissue transglutaminase on retinoic acid-induced cellular differentiation and protection against apoptosis. J Biol Chem 276:33582-33587
58. Boehm JE, Singh U, Combs C, Antonyak MA, Cerione RA (2002) Tissue transglutaminase protects against apoptosis by modifying the tumor suppressor protein p110 Rb. J Biol Chem 277:20127-20130